IRIS
QUINTARELLI, CONCETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.080
NA - Nord America 2.715
EU - Europa 2.346
SA - Sud America 330
AF - Africa 72
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
Totale 8.552
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.598
SG - Singapore 1.412
RU - Federazione Russa 968
IT - Italia 553
CN - Cina 526
VN - Vietnam 481
HK - Hong Kong 324
BR - Brasile 272
DE - Germania 140
FR - Francia 125
FI - Finlandia 112
UA - Ucraina 105
IE - Irlanda 82
CA - Canada 75
JP - Giappone 75
GB - Regno Unito 70
NL - Olanda 70
IN - India 54
BD - Bangladesh 51
SE - Svezia 30
PL - Polonia 25
MX - Messico 22
ZA - Sudafrica 22
KR - Corea 21
AR - Argentina 18
ES - Italia 18
IQ - Iraq 17
PH - Filippine 17
ID - Indonesia 15
EC - Ecuador 11
TH - Thailandia 11
TR - Turchia 11
LT - Lituania 10
CI - Costa d'Avorio 9
UZ - Uzbekistan 9
AT - Austria 8
CL - Cile 8
PK - Pakistan 8
MA - Marocco 7
AE - Emirati Arabi Uniti 6
CO - Colombia 6
EG - Egitto 6
ET - Etiopia 6
LV - Lettonia 6
SA - Arabia Saudita 5
TW - Taiwan 5
BE - Belgio 4
BO - Bolivia 4
DZ - Algeria 4
HR - Croazia 4
PY - Paraguay 4
VE - Venezuela 4
BW - Botswana 3
GE - Georgia 3
HU - Ungheria 3
IR - Iran 3
JM - Giamaica 3
JO - Giordania 3
KW - Kuwait 3
KZ - Kazakistan 3
SN - Senegal 3
AL - Albania 2
AU - Australia 2
AZ - Azerbaigian 2
CH - Svizzera 2
CW - ???statistics.table.value.countryCode.CW??? 2
EU - Europa 2
GT - Guatemala 2
IL - Israele 2
MK - Macedonia 2
ML - Mali 2
MY - Malesia 2
PA - Panama 2
PE - Perù 2
RO - Romania 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
CU - Cuba 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GN - Guinea 1
GP - Guadalupe 1
GY - Guiana 1
HT - Haiti 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
Totale 8.536
Salva come PNG Salva come JPEG
Città #
Singapore 645
San Jose 413
Hong Kong 318
Ashburn 224
Moscow 222
Chandler 198
Beijing 147
Ho Chi Minh City 113
Hanoi 102
Millbury 87
Santa Clara 87
Lauterbourg 75
Los Angeles 71
The Dalles 69
Tokyo 65
Hefei 64
Napoli 61
Munich 60
Amsterdam 56
Council Bluffs 49
Rome 49
Dong Ket 48
Princeton 46
Naples 43
Nanjing 40
Buffalo 38
New York 36
São Paulo 34
Turku 34
Des Moines 33
Frisco 33
Boston 32
Redondo Beach 32
Jacksonville 30
Milan 29
Wilmington 26
Lawrence 24
Dallas 23
Toronto 23
Frankfurt am Main 22
Helsinki 22
Orem 22
Brooklyn 21
Chennai 21
London 21
Ottawa 21
Da Nang 19
Dublin 19
Warsaw 19
Haiphong 18
Montreal 17
Atlanta 15
Seattle 15
Johannesburg 13
Nuremberg 13
Poplar 13
Denver 12
San Francisco 12
Falkenstein 11
Falls Church 11
Houston 10
Jiaxing 10
Mexico City 10
Rio de Janeiro 10
Seoul 10
Lappeenranta 9
Mumbai 9
Nanchang 9
Phoenix 9
Shenyang 9
Tianjin 9
Brescia 8
Chongqing 8
Fairfield 8
Redwood City 8
Biên Hòa 7
Brasília 7
Changsha 7
Charlotte 7
Chicago 7
Guidonia 7
Stockholm 7
Tashkent 7
Guangzhou 6
Ninh Bình 6
Quận Ba 6
Raleigh 6
Riga 6
Salerno 6
Turin 6
Verona 6
Addis Ababa 5
Ankara 5
Augusta 5
Florence 5
Hải Dương 5
Manchester 5
Porto Alegre 5
Pune 5
Salvador 5
Totale 4.421
Salva come PNG Salva come JPEG
Nome #
Frequenza delle mutazioni c-kit in pazienti affetti da Leucemia mieloide acuta (LAM) caratterizzata da alterazioni del gene del core binding factor (CBF) 427
NANOG: ITS ROLE IN THE TKI RESISTANCE OBSERVED IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA 214
Transition index: new original tool to identify subsets overlapping MPN phenotypes. 176
Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies 171
A Novel Score to Predict Interferon-Alpha Therapy Responsiveness in Patients with Essential Thrombocythemia 168
UNA BASSA ESPRESSIONE DELLA FOSFATASI SHP-1 CORRELA CON LA RESI-STENZA AL TRATTAMENTO CON INIBITORI DELLE TIROSIN KINASI IN PAZIENTIAFFETTI DA LEUCEMIA MIELOIDE CRONICA 162
Spleen is the dark side of essential Thrombocitemia 158
Advanced-stage Hodgkin Lymphoma: US/Chest Radiography for Detection of Relapse in Patients in First Complete Remission—A Randomized Trial of Routine Surveillance Imaging Procedures 152
MOLECULAR EVALUATION OF ZNF224 MRNA EXPRESSION IN CML PATIENTS AS A NOVEL DETERMINANT OF TKI RESPONSIVENESS 152
SPLEEN VOLUME IS THE MOST ACCURATE PARAMETER TO AVOID UNDERSTIMATION OF 25% SPLENOMEGALIC PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA 147
B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies 144
L'ATTIVITÀ DEGLI INIBITORI DI TIROSINA KINASI (TKI) SULLA PROLIFERAZIONE E L'ATTIVAZIONE DELLE CELLULE T 143
Adoptive immunotherapy using prame-specific t cells in medulloblastoma 143
WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene 142
CLINICAL RELEVANCE IN CHRONIC MYELOID LEUKEMIA OF DELETION AND INSERTION EVENTS IN THE TYROSINE KYNASE DOMAIN OF BCR-ABL 136
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells 133
Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib. 132
SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best 130
Role of interferon-γ in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation 130
Cytotoxic T lymphocytes directed to the Preferentially Expressed Antigen of Melanoma (PRAME) target chronic myeloid leukemia. 125
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. 124
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical relation. 123
PD-1-induced T cell exhaustion is controlled by a Drp1-dependent mechanism 122
Decitabine up-regulates the expression of the cancer-associate prame antigen in early chronic phase CML cells. 116
Preferentially expressed antigen of melanoma (PRAME)-specific cytotoxic T-Lymphocytes (CTLs) and transgenic T cells to target chronic myelogenous leukemia (CML) 115
Molecular monitoring in chronic myeloid leukemia (CML) 115
Human CAR NK cells: A new non-viral method allowing high efficient transfection and strong tumor cell killing 111
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma 110
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. 108
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia 108
Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients 106
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. 105
The biological resources and molecule archives organization: Turn a need into an opportunity for the Smart Specialization Strategy of the Lazio region 104
Co-Expression of a Chimeric Antigen Receptor Targeting CD19 (CAR19), Optimized Human IL-15, and iCaspase9 To Enhance the Activity and Safety of Cytotoxic T Lymphocytes 102
A small animal in vivo imaging model of expanded vs. unexpanded UCB stem cells reveals differential patterns of engraftment 101
Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells 101
Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. 99
Early detection of residual disease by Q-RT-PCR of the hybrid BCR/ABL transcript is a powerful predictor of treatment response in adult Philadelphia - Positive acute lymphoblastic leukemia. 99
CLINICAL OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH DELETION AND INSERTION EVENTS (DI) IN THE TYROSINE KINASE DOMAIN OF BCR-ABL 98
Gene transfer of IL-7R alpha (IL-7R alpha) on antigen-specific cytotoxic T cells (CTLs) restores their ability to respond to IL-7 cytokine 97
Generation of Epstein Barr Virus Specific Cytotoxic T Lymphocytes (EBV-CTLs) Resistant to the Immunosuppressive Drug Tacrolimus (FK506) 97
Gene therapy to improve function of T cells for adoptive immunotherapy. 96
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model 96
Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring 96
Allogeneic CAR T cells: A new player in the field and the peculiar opportunities of the hospital exemption path 94
Transgenic expression of inducible caspase9 suicide gene for in vivo elimination of antigen specific cytotoxic T cells (CTLs) engineered to produce cytokines. 93
Induction of PRAME-specific immunity by overlapping pentadecapeptides in patients with hematologic malignancies 92
Overcoming challenges in CAR T-cell product CGMP release 91
Generation of EBV specific cytotoxic T lymphocytes (EBV-CTLs) resistant to the immunosuppressive drug FK506 88
Ethics-aware data governance (Vision Paper) 88
Hepatitis B virus reactivation after fludarabine-based regiments for indolent non-Hodgkin’s lymphomas: high prevalence of acquired viral genomic mutations. 87
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. 85
Polyclonal PRAME-Specific Cytotoxic T Lymphocytes Generated Using Protein-Spanning Pools of Overlapping Pentadecapeptides Target Chronic Myeloid Leukemia 84
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. 82
Engineering CD19-Redirected T Lymphocytes to Enhance Their Safety and Efficacy 82
Stimuli-responsive nanoparticle-assisted immunotherapy: A new weapon against solid tumours 82
HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks 81
Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ΔCD19 81
Safely Improving the in Vivo Survival of Tumor Specific Cytotoxic T Lymphocytes by Co-Transfer of IL7 Receptor Alpha Chain and icaspase9 80
Transgenic expression of IL15 selectively expands antigen specific cytotoxic T cells (CTLs) enhancing their anti-tumor effect in vivo. 80
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells 79
European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring 77
Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma 76
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). 72
Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma 70
Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse 69
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7 67
Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients 67
Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy 65
The immune system of children: the key to understanding SARS-CoV-2 susceptibility? 65
A novel MLL/AF4 fusion gene lacking the AF4 transactivating domain in infant acute lymphoblastic leukemia. 64
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia 59
Generation and expansion of PRAME-specific cytotoxic T-lymphocytes for adoptive T-cell therapy of hematological malignancies. 57
NK Cell-Based Immunotherapy for Hematological Malignancies 57
Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study 56
Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia 55
Preservation of antigen-specific functions of αβ T cells and B cells removed from hematopoietic stem cell transplants suggests their use as an alternative cell source for advanced manipulation and adoptive immunotherapy 54
Identification of Annexin A1 interacting proteins in chronic myeloid leukemia KCL22 cells 51
Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia. 51
The EURE-CART project as a prototype model for CAR T-cell immunotherapy in Europe 47
MicroRNAs in neuroblastoma: Biomarkers with therapeutic potential 46
Autologous CD19-Targeting CAR T Cells in a Patient With Refractory Juvenile Dermatomyositis 43
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis 42
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. 10
A biodegradable hydrogel based on carboxymethyl cellulose/silver nanoparticles for wound closures 5
GD2 Target Antigen and CAR T Cells: Does It Take More Than Two to Tango? 5
The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors 5
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting 4
An in vivo CRISPR screen unveils promising target genes to improve CAR-T cell efficacy in a solid tumor model 4
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML 4
The immune response as a double-edged sword: The lesson learnt during the COVID-19 pandemic 4
GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapy 4
Patient- and xenograft-derived organoids recapitulate pediatric brain tumor features and patient treatments 3
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma 3
GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape 3
SARS-CoV-2 infection of thymus induces loss of function that correlates with disease severity 3
Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies 3
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. Reply 3
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial 3
Identification of New Soluble Factors Correlated With the Development of Graft Failure After Haploidentical Hematopoietic Stem Cell Transplantation 3
Totale 8.662
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.086
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.086
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202153 0 0 0 0 0 0 0 0 0 0 0 53
2021/2022495 34 2 5 9 5 17 7 17 82 23 130 164
2022/2023511 73 32 20 10 65 57 8 67 92 47 24 16
2023/2024309 17 51 46 23 15 25 6 23 10 9 64 20
2024/20252.223 101 155 9 26 59 100 224 147 128 222 751 301
2025/20264.345 482 303 435 442 718 162 479 248 434 359 248 35
Totale 8.717